Buprenorphine as an adjuvant to 0.5% ropivacaine for ultrasound-guided supraclavicular brachial plexus block: A randomized, double-blind, prospective study
Context: Ultrasound-guided supraclavicular brachial plexus block is ideal for upper limb surgical procedures. Buprenorphine used as an adjuvant to ropivacaine may prolong analgesia. Aims: The aim is to assess the analgesic efficacy and safety of buprenorphine added to 0.5% ropivacaine solution. Sett...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2017-01-01
|
Series: | Indian Journal of Pain |
Subjects: | |
Online Access: | http://www.indianjpain.org/article.asp?issn=0970-5333;year=2017;volume=31;issue=2;spage=112;epage=118;aulast=Jain |
id |
doaj-c11e16b423914d9f84d7b32ef9863214 |
---|---|
record_format |
Article |
spelling |
doaj-c11e16b423914d9f84d7b32ef98632142020-11-25T00:06:14ZengWolters Kluwer Medknow PublicationsIndian Journal of Pain0970-53332017-01-0131211211810.4103/ijpn.ijpn_23_17Buprenorphine as an adjuvant to 0.5% ropivacaine for ultrasound-guided supraclavicular brachial plexus block: A randomized, double-blind, prospective studyNeena JainArvind KhareShubham KhandelwalPooja MathurMaina SinghVeena MathurContext: Ultrasound-guided supraclavicular brachial plexus block is ideal for upper limb surgical procedures. Buprenorphine used as an adjuvant to ropivacaine may prolong analgesia. Aims: The aim is to assess the analgesic efficacy and safety of buprenorphine added to 0.5% ropivacaine solution. Settings and Design: This prospective, double-blind, randomized study was conducted on 60 adult patients of the American Society of Anesthesiologists physical Status I and II undergoing various upper limb surgeries under ultrasound-guided supraclavicular brachial plexus block. Subjects and Methods: Patients were allocated into two groups of 30 each to receive either 30 ml 0.5% ropivacaine with 1 ml buprenorphine (0.3 mg) (Group B) or 30 ml 0.5% ropivacaine with 1 ml normal saline (Group C) for supraclavicular brachial plexus block. Onset, duration, and quality of sensory block and motor block; duration of analgesia and side effects were observed. Results: The mean duration of analgesia was significantly longer in Group B (868.2 ± 77.78 min) than in Group C (439.3 ± 51.19 min). The mean duration of motor and sensory block were significantly longer in Group B (451.8 ± 57.18 min) and (525.8 ± 50 min), respectively, than in Group C (320.5 ± 43.62 min) and (373 ± 53.78 min), respectively (P < 0.05). Conclusions: Addition of buprenorphine to ropivacaine for ultrasound-guided supraclavicular brachial plexus block prolonged the duration of sensory and motor blockade and postoperative analgesia without an increase in side effects.http://www.indianjpain.org/article.asp?issn=0970-5333;year=2017;volume=31;issue=2;spage=112;epage=118;aulast=JainAnalgesiabrachial plexus blockbuprenorphineropivacaineultrasound |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Neena Jain Arvind Khare Shubham Khandelwal Pooja Mathur Maina Singh Veena Mathur |
spellingShingle |
Neena Jain Arvind Khare Shubham Khandelwal Pooja Mathur Maina Singh Veena Mathur Buprenorphine as an adjuvant to 0.5% ropivacaine for ultrasound-guided supraclavicular brachial plexus block: A randomized, double-blind, prospective study Indian Journal of Pain Analgesia brachial plexus block buprenorphine ropivacaine ultrasound |
author_facet |
Neena Jain Arvind Khare Shubham Khandelwal Pooja Mathur Maina Singh Veena Mathur |
author_sort |
Neena Jain |
title |
Buprenorphine as an adjuvant to 0.5% ropivacaine for ultrasound-guided supraclavicular brachial plexus block: A randomized, double-blind, prospective study |
title_short |
Buprenorphine as an adjuvant to 0.5% ropivacaine for ultrasound-guided supraclavicular brachial plexus block: A randomized, double-blind, prospective study |
title_full |
Buprenorphine as an adjuvant to 0.5% ropivacaine for ultrasound-guided supraclavicular brachial plexus block: A randomized, double-blind, prospective study |
title_fullStr |
Buprenorphine as an adjuvant to 0.5% ropivacaine for ultrasound-guided supraclavicular brachial plexus block: A randomized, double-blind, prospective study |
title_full_unstemmed |
Buprenorphine as an adjuvant to 0.5% ropivacaine for ultrasound-guided supraclavicular brachial plexus block: A randomized, double-blind, prospective study |
title_sort |
buprenorphine as an adjuvant to 0.5% ropivacaine for ultrasound-guided supraclavicular brachial plexus block: a randomized, double-blind, prospective study |
publisher |
Wolters Kluwer Medknow Publications |
series |
Indian Journal of Pain |
issn |
0970-5333 |
publishDate |
2017-01-01 |
description |
Context: Ultrasound-guided supraclavicular brachial plexus block is ideal for upper limb surgical procedures. Buprenorphine used as an adjuvant to ropivacaine may prolong analgesia. Aims: The aim is to assess the analgesic efficacy and safety of buprenorphine added to 0.5% ropivacaine solution. Settings and Design: This prospective, double-blind, randomized study was conducted on 60 adult patients of the American Society of Anesthesiologists physical Status I and II undergoing various upper limb surgeries under ultrasound-guided supraclavicular brachial plexus block. Subjects and Methods: Patients were allocated into two groups of 30 each to receive either 30 ml 0.5% ropivacaine with 1 ml buprenorphine (0.3 mg) (Group B) or 30 ml 0.5% ropivacaine with 1 ml normal saline (Group C) for supraclavicular brachial plexus block. Onset, duration, and quality of sensory block and motor block; duration of analgesia and side effects were observed. Results: The mean duration of analgesia was significantly longer in Group B (868.2 ± 77.78 min) than in Group C (439.3 ± 51.19 min). The mean duration of motor and sensory block were significantly longer in Group B (451.8 ± 57.18 min) and (525.8 ± 50 min), respectively, than in Group C (320.5 ± 43.62 min) and (373 ± 53.78 min), respectively (P < 0.05). Conclusions: Addition of buprenorphine to ropivacaine for ultrasound-guided supraclavicular brachial plexus block prolonged the duration of sensory and motor blockade and postoperative analgesia without an increase in side effects. |
topic |
Analgesia brachial plexus block buprenorphine ropivacaine ultrasound |
url |
http://www.indianjpain.org/article.asp?issn=0970-5333;year=2017;volume=31;issue=2;spage=112;epage=118;aulast=Jain |
work_keys_str_mv |
AT neenajain buprenorphineasanadjuvantto05ropivacaineforultrasoundguidedsupraclavicularbrachialplexusblockarandomizeddoubleblindprospectivestudy AT arvindkhare buprenorphineasanadjuvantto05ropivacaineforultrasoundguidedsupraclavicularbrachialplexusblockarandomizeddoubleblindprospectivestudy AT shubhamkhandelwal buprenorphineasanadjuvantto05ropivacaineforultrasoundguidedsupraclavicularbrachialplexusblockarandomizeddoubleblindprospectivestudy AT poojamathur buprenorphineasanadjuvantto05ropivacaineforultrasoundguidedsupraclavicularbrachialplexusblockarandomizeddoubleblindprospectivestudy AT mainasingh buprenorphineasanadjuvantto05ropivacaineforultrasoundguidedsupraclavicularbrachialplexusblockarandomizeddoubleblindprospectivestudy AT veenamathur buprenorphineasanadjuvantto05ropivacaineforultrasoundguidedsupraclavicularbrachialplexusblockarandomizeddoubleblindprospectivestudy |
_version_ |
1725423227545583616 |